• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Today, There Are More Than 100 Companies Developing More Than 180 Protein Kinase Inhibitory Drugs in More Than 300 Clinical Trials Targeting Around 40 Different Cancer Indications

Posted on: Wednesday, 25 January 2006, 09:01 CST

Research and Markets (http://www.researchandmarkets.com/reports/c31488) has announced the addition of Protein Kinase Inhibitors in Oncology: Drug Pipeline Update 2006 to their offering.

Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. However, these three successful drugs are just the top of an emerging line of therapy. Given the fact that they all target tyrosine kinases and that kinase mutations can cause patients to become resistant to these drugs, there is plenty of room for more competition. Today, there are more than 100 companies developing more than 180 protein kinase inhibitory drugs in more than 300 clinical trials targeting around 40 different cancer indications. The number of protein kinase targets has increased to over 50 different molecular targets in just a few years.

Investigators Includes more than 100 investigators

Drug name & Synonyms Lists commercial, generic and code names for drugs. In all more than 300 names

Developmental stage Contains more than 180 PKI drugs in development for cancer:

> 10 projects in Phase III

> 100 projects in Phase II

> 60 projects in Phase I

> 60 projects in Preclinical

Cancer Indications PKI drugs in development for over 40 cancer indications

-- Breast cancer

-- Colorectal cancer

-- Hematological cancers

-- Lung cancer

-- Melanoma

-- Prostate cancer

Etc

Target More than 50 different targets. Examples:

-- Aurora kinase A & B

-- CD22 antigen

-- Cell division cycle 2, G1 to S and G2 to M

-- CHK1 & CHK2 checkpoint homologue (S pombe)

-- Cyclin-dependent kinase 1A, 2, 4, 6, 7, 9

-- Epidermal growth factor receptor

-- FK506 binding protein 12-rapamycin associated protein 1

-- fms-related tyrosine kinase 1,3 & 4

-- met proto-oncogene

-- Mitogen-activated protein kinase 14

-- Phosphoinositide-3-kinase, catalytic, alpha & gamma polypeptide

-- Protein kinase C, alpha 6 beta 1

-- TEK tyrosine kinase, endothelial

-- Topoisomerase (DNA) II alpha 170kDa

-- v-raf-1 Murine leukaemia viral oncogene homologue 1

-- v-src Sarcoma viral oncogene homologue

Etc

Compound Lists compound name or type of compound:

-- Antibodies

-- Chemical names

-- Enzymes

-- Nucleotides

-- Peptides

-- Proteins

-- Ribozymes

Etc.

Description Progress analysis and review of drug development.

How May Drug Pipeline Update Be of Use?

Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

Find competitors, collaborations partners, M&A candidates etc.

Jump start competitive drug intelligence operations

Excellent starting point for world wide benchmarking

Compare portfolio and therapy focus with your peers

Speed up pro-active in-/outlicensing strategy work

Fast and easy way of tracking drugs using search engines; just one click and you may search World Wide Web and PubMed for any drug with all its synonyms.

Drug Pipeline Update is Delivered to You as a CD-ROM application

Drug Pipeline Update is fitted into a CD-ROM based application, for your intelligent usage:

Smart CD-ROM application, which makes it easy to use and navigate by

Multiple search and sort functions included

Drug data is linked to search engines like Google and PubMed

Direct links to web pages from inside the application

Found information is easily shared with others over email, file export or in print

System Requirements

AMD-Athlon/Pentium II PC

Windows 98/NT4/2000/ME/XP

8x-speed CD Rom drive

SVGA 16 bit display. (32 bit recommended)

32 MB of available RAM (128 MB recommended)

Internet access (to test web-enabled presentations)

For more information visit http://www.researchandmarkets.com/reports/c31488

Source: Business Wire

More News in this Category